Individual results may vary

"Alnylam Assist®, and our Case
Manager, really helped us
navigate the approval process."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Individual results may vary

"Alnylam Assist®, and our Case
Manager, really helped us
navigate the approval process."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Alnylam Assist® is experienced in providing support services to patients on GIVLAARI® (givosiran)

The Alnylam Assist® program offers you support throughout your treatment with GIVLAARI in 3 key areas: understanding benefits, eligibility for financial assistance, and disease and product education.

Once you and your healthcare provider choose to begin treatment with GIVLAARI, you should complete a Start Form together and submit it to Alnylam Assist®.

Upon receipt of the Start Form, an Alnylam Case Manager will reach out to you within 2 business days to discuss:

Navigating your insurance benefits

We will review your insurance coverage and answer questions about your insurance benefits for GIVLAARI.

Financial assistance*

Alnylam offers financial assistance programs for eligible patients. After being prescribed an Alnylam product, you can talk to a Case Manager to learn if you may be eligible. Below are examples of 2 Alnylam Financial Assistance programs.

  • I have insurance but have concerns about paying for an Alnylam product
    • Our Commercial Copay Program covers certain out-of-pocket costs for eligible patients with commercial insurance
  • I’m uninsured, or I have insurance but do not have coverage for an Alnylam product
    • Our Patient Assistance Program may be able to provide you with one of Alnylam’s products at no cost if you’re eligible

*Individuals must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist® Commercial Copay Program. Out-of-pocket costs for the administration of Alnylam products will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

For more information about Alnylam Assist® or to access downloadable materials:

Alnylam Assist® logo
Contact Info

Visit: AlnylamAssist.com

Call: 1-833-256-2748

Monday-Friday, 8 AM-6 PM

Experienced team members

An Alnylam Case Manager

When you and your healthcare provider choose to begin treatment with GIVLAARI, you will be partnered with an Alnylam Case Manager. Case managers are experienced in:

Check mark Helping you get started on treatment
Check mark Determining your eligibility for financial assistance
Check mark Navigating your insurance benefits
Check mark Providing you with product support throughout your treatment

An Alnylam Patient Education Liaison (PEL)

Our Patient Education Liaisons have backgrounds in nursing and are experienced in educating people and their families about matters related to acute hepatic porphyria (AHP). Your PEL can help you in a variety of ways, such as:

Check mark Supporting you with disease education
Check mark Answering questions about treatment with GIVLAARI
Check mark Providing you with product education
Check mark Connecting you to additional resources

The purpose of the PELs is to provide education to patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.

 

IMPORTANT SAFETY INFORMATION

Do not use GIVLAARI® (givosiran) if you have ever had a severe allergic reaction to GIVLAARI.

  • Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:

    • Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
    • Breathing problems or wheezing
    • Feeling dizzy or fainting
    • Rash or hives
    • Itching

    If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

  • Your doctor will check your liver function by doing blood tests:

    • Before you start using GIVLAARI
    • Once a month for the first 6 months of treatment
    • And when they think it is needed

    If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

  • Your doctor will check how your kidneys are working while you are using GIVLAARI.

  • GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

    Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

  • GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

  • Cases of acute pancreatitis including some that were severe, have been reported in patients receiving GIVLAARI. If you have a severe case of acute pancreatitis your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-8 00-FDA -1088.


WHAT IS GIVLAARI?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.


For additional information about GIVLAARI, please see full Prescribing Information.